Neuroprotective effects of D3 dopamine receptor agonists (Q34237471)

31 July 2017

Neuroprotective effects of D3 dopamine receptor agonists (English)

1 reference

31 July 2017

P M. Carvey

1

1 reference

PubMed ID

11331189

31 July 2017

S O. McGuire

series ordinal

2

1 reference

PubMed ID

11331189

31 July 2017

Z D. Ling

series ordinal

3

1 reference

31 July 2017

1 July 2001

1 reference

31 July 2017

11

1 reference

Parkinsonism and Related Disorders

inferred from page(s)

published in

1 reference

31 July 2017

7

1 reference

31 July 2017

3

1 reference

31 July 2017

213-223

1 reference

Parkinson's disease: pathophysiology

31 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

First trimester development of the human nigrostriatal dopamine system.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Pramipexole--a new dopamine agonist for the treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

A comparative review of new antipsychotics

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Monoamine oxidase molecular activity in platelets of parkinsonian and demented patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Structure/function in neuroprotection and apoptosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

1 reference

7 January 2021

Programmed cell death: does it play a role in Parkinson's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Lisuride prevents learning and memory impairment and attenuates the increase in extracellular dopamine induced by transient global cerebral ischemia in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Compensatory mechanisms in degenerative neurologic diseases. Insights from parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Alterations in striatal neurotrophic activity induced by dopaminergic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Striatal extracts from patients with Parkinson's disease promote dopamine neuron growth in mesencephalic cultures.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Free-radical toxicity and antioxidant medications in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Therapeutic potential of nerve growth factors in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Development and survival of neurons in dissociated fetal mesencephalic serum-free cell cultures: I. Effects of cell density and of an adult mammalian striatal-derived neuronotrophic factor (SDNF).

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Behavioural effects in the rat of the putative dopamine D3 receptor agonist 7-OH-DPAT: comparison with quinpirole and apomorphine.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Effect of pergolide on endogenous and exogenous L-DOPA metabolism in the rat striatum: a microdialysis study

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged-Fischer-344 rats

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Lazaroid treatment prevents death of cultured rat embryonic mesencephalic neurons following glutathione depletion.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Autoradiographic localisation of D3-dopamine receptors in the human brain using the selective D3-dopamine receptor agonist (+)-[3H]PD 128907.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Does oxidative stress participate in nerve cell death in Parkinson's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Neuronal vulnerability in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration?

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Nitric oxide synthase and neuronal vulnerability in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Oxidative stress and the pathogenesis of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Understanding cell death in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Expression of bcl-2 inhibits necrotic neural cell death.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Bromocriptine scavenges methamphetamine-induced hydroxyl radicals and attenuates dopamine depletion in mouse striatum

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Astrocytes promote or impair the survival and function of embryonic ventral mesencephalon co-grafts: effects of astrocyte age and expression of recombinant brain-derived neurotrophic factor.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Comparison of the neurotoxicity of dihydroxyphenylalanine stereoisomers in cultured dopamine neurons

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Partial purification of a pramipexole-induced trophic activity directed at dopamine neurons in ventral mesencephalic cultures

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Levodopa toxicity and apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Mitochondrial dysfunction in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Determinants of neuronal vulnerability in neurodegenerative diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Scavenging effects of dopamine agonists on nitric oxide radicals.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine neurotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

An introduction to the free radical hypothesis in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

A radical hypothesis for neurodegeneration

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Attempts to obtain neuroprotection in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Dopamine agonists and neuroprotection in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Dopamine D2 receptor agonists protect against ischaemia-induced hippocampal neurodegeneration in global cerebral ischaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Effects of pergolide treatment on in vivo hydroxyl free radical formation during infusion of 6-hydroxydopamine in rat striatum.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Oxidative stress and Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

In vitro studies on central dopaminergic neurons' development.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Experimental developments in movement disorders: update on proposed free radical mechanisms.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Increased cerebrospinal fluid concentration of nitrite in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

NGF, BDNF and NT-5, but not NT-3 protect against MPP+ toxicity and oxidative stress in neonatal animals.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Specification and survival of dopaminergic neurons in the mammalian midbrain

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Release of endogenous dopamine in cultured mesencephalic neurons: influence of dopaminergic agonists and glucocorticoid antagonists.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Neuroprotective effects of the dopamine agonists pramipexole and bromocriptine in 3-acetylpyridine-treated rats.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Bcl-2 prevents apoptotic mitochondrial dysfunction by regulating proton flux

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Evaluation of the pro-oxidant and antioxidant actions of L-DOPA and dopamine in vitro: implications for Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Chronic levodopa impairs morphological development of grafted embryonic dopamine neurons

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Behavioral and neurochemical data suggest functional differences between dopamine D2 and D3 receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Inhibitory effects of bromocriptine on phospholipid peroxidation induced by dopa and iron

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Mitochondria in neurodegenerative apoptosis: an opportunity for therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Pharmacological approaches to counter the toxicity of Dopa.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

A Bcl-2 antisense oligonucleotide increases alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) toxicity in cortical cultures.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyride neurotoxicity is attenuated in mice overexpressing Bcl-2.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

Antioxidant properties of bromocriptine, a dopamine agonist.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900061-4

7 January 2021

10.1016/S1353-8020(00)00061-4

Identifiers

DOI

1 reference

31 July 2017

1 reference

PubMed ID

11331189